Skip to main content
13 April 2021
Last updated:
Tuesday 13 April 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
    • Who We Are
    • Editorial Board
    • Editorial Policy
  • Research Directory
  • Contact Us

Editorial Policy

MedNous is an independent source of information and analysis for professionals in the life sciences. It is free from bias and does not accept sponsorship of any kind. The company will accept advertising for its print publication. However advertising will not be accepted on the website, except for recruitment advertising. For further information, please contact [email protected].

MedNous is produced by Evernow Publishing Ltd, a family-owned concern, whose founding director, William Ellington, is a journalist.

The purpose of the company’s publications is to educate and inform and to stimulate discussion. The publications have a policy of naming their sources and publishing corrections in case of errors.

The contents of the print publication and the website are protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and distributed by electronic or other means without the prior written consent of Evernow Publishing Ltd. While due care has been used in assembling information in the print publication and on the website, the publisher makes no claim that it is free of error or fit for any particular purpose. In addition, the publisher does not accept liability to anyone for the consequences of any decision or action taken (or which any person refrains from taking) in reliance on any information contained herein.

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

René Hoet becomes CSO at Montis Biosciences
Wednesday March 31 2021
Pan Cancer T makes board appointments
Wednesday March 31 2021
Björn Englund appointed CEO at Opterion
Wednesday March 31 2021
Sven Zimmermann joins Inotrem
Wednesday March 31 2021
New director at Mission Therapeutics
Wednesday March 31 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.